An overview of PsoProtect’s current data.

Current Data

We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.

Click here to read our recently published scientific research paper detailing the PsoProtect data, entitled ‘Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study‘.

0
Total number of cases reported

Summary data from PsoProtect’s first 885 cases.

Cases reported by country of assessment (≥20 cases):
Country Cases
United Kingdom 264
Italy 129
Spain 99
France 94
Netherlands 62
United States 47
Portugal 38
Rest of the world 152

Average age: 50 years
Phenotype of psoriasis: 864 plaque psoriasis, 21 pustular psoriasis
Average BMI: 27.7 kg/m2
Average number of days of symptoms from COVID-19: 12 days

Confirmed COVID-19:

Gender:

Smoking history:

Concurrent psoriatic arthritis:

Severity of psoriasis at time of onset of COVID-19 (PGA):

Hospitalization required due to COVID-19:

Systemic medication for psoriasis at time of onset of COVID-19:

Medication Count
Biologic – TNF inhibitor 225
Biologic – IL-23 inhibitor 226
Biologic – IL-17 inhibitor 152
Conventional systemic agent 106
Small molecule inhibitor 43
Biologic and conventional systemic co-therapy 27
Small molecule inhibitor and conventional systemic co-therapy 3
No systemic agent 99
Unknown (participating in clinical trial) 4

Was the biologic medication for psoriasis stopped during COVID-19 infection:

Outcome of COVID-19: